Score:
9.5/15
Analyze what earned this score 🔥
GS3
Economy
15 marks
India's pharmaceutical industry is increasingly becoming a strategic pillar of the economy and global healthcare. In this context, examine the implications of the proposed U.S. tariffs on generic medicines for India's pharmaceutical sector and discuss the policy measures needed to strengthen its global competitiveness.
Student’s Answer
Evaluation by SuperKalam
Analyze what earned this score 🔥
The Indian pharmaceutical industry, recognized globally as 'Pharmacy of the world', supplies over 20% of global generic medicines. However, the proposed US tariff announces phased tariff structure targeting imported generic drugs. Announcement ⇒ July 2026. Grace Period (0% tariff) ⇒ August 2026 - August 2028 100% tariff ⇒ August 2028 - August 2029 200% tariff (Permanent) ⇒ August 2029 onwards
The Indian pharmaceutical industry, recognized globally as 'Pharmacy of the world', supplies over 20% of global generic medicines. However, the proposed US tariff announces phased tariff structure targeting imported generic drugs. Announcement ⇒ July 2026. Grace Period (0% tariff) ⇒ August 2026 - August 2028 100% tariff ⇒ August 2028 - August 2029 200% tariff (Permanent) ⇒ August 2029 onwards
# Implications of Proposed US tariff on India's Pharma Sector 1. Squeezing of Profit Margins - US is India's largest market, accounting for 37% of its pharma exports. Tariffs will compress the margins of Indian generic drugs. 2. 'Cost Arbitrage' - Many Indian generics are priced 7 to 10 times lower than branded US alternates. Indian exporters may retain market access by partially passing on costs. 3. Forced Capital Realignment - Indian companies will face intense pressure to shift from domestic manufacturing to high cost US-based brownfield acquisitions or local contract development & manufacturing organizations.
# Implications of Proposed US tariff on India's Pharma Sector 1. Squeezing of Profit Margins - US is India's largest market, accounting for 37% of its pharma exports. Tariffs will compress the margins of Indian generic drugs. 2. 'Cost Arbitrage' - Many Indian generics are priced 7 to 10 times lower than branded US alternates. Indian exporters may retain market access by partially passing on costs. 3. Forced Capital Realignment - Indian companies will face intense pressure to shift from domestic manufacturing to high cost US-based brownfield acquisitions or local contract development & manufacturing organizations.
# Policy Measures to strengthen Global Competitiveness 1. Enhance PLI schemes - Pivot the existing PLI scheme towards high-value segments like Biosimilars, Complex Generics & Orphan Drugs, where higher margins can absorb external tariff shocks. 2. Market Diversification via FTAs - Actively conclude ongoing FTA with EU, UK, Latin American blocs to dilute 37% export concentration risk in US. 3. Transition to an innovation led ecosystem through sovereign R&D funding with establishment of National Pharma Research Fund.
# Policy Measures to strengthen Global Competitiveness 1. Enhance PLI schemes - Pivot the existing PLI scheme towards high-value segments like Biosimilars, Complex Generics & Orphan Drugs, where higher margins can absorb external tariff shocks. 2. Market Diversification via FTAs - Actively conclude ongoing FTA with EU, UK, Latin American blocs to dilute 37% export concentration risk in US. 3. Transition to an innovation led ecosystem through sovereign R&D funding with establishment of National Pharma Research Fund.
The proposed US tariff shows vulnerability of pharma in global markets. By swiftly executing structural reforms - transitioning from 'Make in India' to 'Discover & Innovate in India' - the domestic pharma sector can turn this protectionist challenge into an opportunity to secure long term, resilient leadership.
The proposed US tariff shows vulnerability of pharma in global markets. By swiftly executing structural reforms - transitioning from 'Make in India' to 'Discover & Innovate in India' - the domestic pharma sector can turn this protectionist challenge into an opportunity to secure long term, resilient leadership.
Your answer demonstrates strong analytical skills with excellent use of current data and strategic thinking. The tariff timeline breakdown and economic impact analysis are particularly well-executed, showing deep understanding of the pharmaceutical sector's global dynamics.
The Indian pharmaceutical industry, recognized globally as 'Pharmacy of the world', supplies over 20% of global generic medicines. However, the proposed US tariff announces phased tariff structure targeting imported generic drugs. Announcement ⇒ July 2026. Grace Period (0% tariff) ⇒ August 2026 - August 2028 100% tariff ⇒ August 2028 - August 2029 200% tariff (Permanent) ⇒ August 2029 onwards
The Indian pharmaceutical industry, recognized globally as 'Pharmacy of the world', supplies over 20% of global generic medicines. However, the proposed US tariff announces phased tariff structure targeting imported generic drugs. Announcement ⇒ July 2026. Grace Period (0% tariff) ⇒ August 2026 - August 2028 100% tariff ⇒ August 2028 - August 2029 200% tariff (Permanent) ⇒ August 2029 onwards
GS2
International Relations
24 Jul, 2026
The proposed U.S - Saudi Civil Nuclear Deal reflects the growing strategic importance of nuclear diplomacy in contemporary international relations. Examine its geopolitical significance and discuss its implications for regional stability and the global nuclear non-proliferation regime.
GS1
Indian Geography
22 Jul, 2026
Water scarcity is increasingly emerging as a developmental challenge rather than merely an environmental concern. Discuss the causes and consequences of water scarcity in India. Suggest measures to ensure long-term water security.
GS2
Indian Polity
21 Jul, 2026
Examine the role of protests and hunger strikes in strengthening democratic accountability in India. Discuss the constitutional, ethical and governance challenges associated with their use in a constitutional democracy, with suitable examples.